MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 200298 | Name: Sapitinib free base
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sapitinib, also known as AZD-8931, is an erbB receptor tyrosine kinase inhibitor with potential antineoplastic activity. erbB kinase inhibitor AZD8931 binds to and inhibits erbB tyrosine receptor kinases, which may result in the inhibition of cellular proliferation and angiogenesis in tumors expressing erbB. The erbB protein family, also called the epidermal growth factor receptor (EGFR) family, plays major roles in tumor cell proliferation and tumor vascularization.

Chemical Structure

Sapitinib free base
Sapitinib free base
CAS#848942-61-0 (free base)

Theoretical Analysis

MedKoo Cat#: 200298

Name: Sapitinib free base

CAS#: 848942-61-0 (free base)

Chemical Formula: C23H25ClFN5O3

Exact Mass: 473.1630

Molecular Weight: 473.93

Elemental Analysis: C, 58.29; H, 5.32; Cl, 7.48; F, 4.01; N, 14.78; O, 10.13

Price and Availability

Size Price Availability Quantity
10mg USD 90.00 Ready to ship
25mg USD 150.00 Ready to ship
50mg USD 250.00 Ready to ship
100mg USD 450.00 Ready to ship
200mg USD 750.00 Ready to ship
500mg USD 1,650.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
848942-61-0 (free base) 1196531-39-1 (fumurate)
Synonym
AZD8931; AZD8931; AZD 8931; Sapitinib
IUPAC/Chemical Name
2-(4-((4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)-N-methylacetamide
InChi Key
DFJSJLGUIXFDJP-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H25ClFN5O3/c1-26-21(31)12-30-8-6-14(7-9-30)33-20-10-15-18(11-19(20)32-2)27-13-28-23(15)29-17-5-3-4-16(24)22(17)25/h3-5,10-11,13-14H,6-9,12H2,1-2H3,(H,26,31)(H,27,28,29)
SMILES Code
O=C(NC)CN1CCC(OC2=CC3=C(NC4=CC=CC(Cl)=C4F)N=CN=C3C=C2OC)CC1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
Sapitinib (AZD-8931) is a reversible, ATP competitive EGFR inhibitor of with IC50s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively.
In vitro activity:
The effects of blocking HER3 on CRC tumor growth were further determined by the subQ xenograft tumor model with treatment of the HER3 inhibitor AZD8931. After HCP-1 cells were injected subQ in the mixture of CM and Matrigel as described above, mice were then treated with either vehicle or AZD8931 by gavage and the tumor growth was monitored over time (Fig. 6). These results showed that LPEC-1 CM treated tumors led to significantly greater tumor growth, as expected. More importantly, AZD8931 significantly inhibited the tumor growth in both CRC CM and LPEC-1 CM-treated CRC tumors compared with tumors without AZD8931 treatment (Fig. 6B). In addition, CRC tumors that were treated by AZD8931 had significantly lower tumor weight compared with tumors not treated with AZD8931, leading to ~2-fold decrease compared to CRC CM treated tumors, and > 4-fold decrease compared to LPEC-1 CM treated tumors (Fig. 6C). Reference: Mol Cancer Res. 2019 Jan; 17(1): 20–29. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318043/
In vivo activity:
When tumors reached 40–50 mm3 (~ 16 days), mice were treated daily with AZD8931 (50 mg/kg) or diluent by oral gavage. As shown in Fig. 3a, treatment with AZD8931 rapidly halts B4B8 tumor progression and causes significant shrinkage of tumors (Fig. 3b) compared to tumor-bearing mice treated with diluent as a control. Thus, B4B8 cells serve as a murine HNSCC model to explore EGFR/ERBB-dependent growth in an in vivo setting. Reference: J Transl Med. 2021; 19: 43. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825244/
Solvent mg/mL mM
Solubility
DMF 33.0 69.60
DMSO 25.0 52.80
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 473.93 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Wang R, Bhattacharya R, Ye X, Fan F, Boulbes DR, Ellis LM. Endothelial Cells Promote Colorectal Cancer Cell Survival by Activating the HER3-AKT Pathway in a Paracrine Fashion. Mol Cancer Res. 2019 Jan;17(1):20-29. doi: 10.1158/1541-7786.MCR-18-0341. Epub 2018 Aug 21. PMID: 30131447; PMCID: PMC6318043. 2. Barlaam B, Anderton J, Ballard P, Bradbury RH, Hennequin LF, Hickinson DM, Kettle JG, Kirk G, Klinowska T, Lambert-van der Brempt C, Trigwell C, Vincent J, Ogilvie D. Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors. ACS Med Chem Lett. 2013 May 31;4(8):742-6. doi: 10.1021/ml400146c. PMID: 24900741; PMCID: PMC4027407. 3. Korpela SP, Hinz TK, Oweida A, Kim J, Calhoun J, Ferris R, Nemenoff RA, Karam SD, Clambey ET, Heasley LE. Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response. J Transl Med. 2021 Jan 23;19(1):43. doi: 10.1186/s12967-021-02706-8. PMID: 33485341; PMCID: PMC7825244. 4. Mu Z, Klinowska T, Dong X, Foster E, Womack C, Fernandez SV, Cristofanilli M. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models. J Exp Clin Cancer Res. 2014 May 30;33(1):47. doi: 10.1186/1756-9966-33-47. PMID: 24886365; PMCID: PMC4061513.
In vitro protocol:
1. Wang R, Bhattacharya R, Ye X, Fan F, Boulbes DR, Ellis LM. Endothelial Cells Promote Colorectal Cancer Cell Survival by Activating the HER3-AKT Pathway in a Paracrine Fashion. Mol Cancer Res. 2019 Jan;17(1):20-29. doi: 10.1158/1541-7786.MCR-18-0341. Epub 2018 Aug 21. PMID: 30131447; PMCID: PMC6318043. 2. Barlaam B, Anderton J, Ballard P, Bradbury RH, Hennequin LF, Hickinson DM, Kettle JG, Kirk G, Klinowska T, Lambert-van der Brempt C, Trigwell C, Vincent J, Ogilvie D. Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors. ACS Med Chem Lett. 2013 May 31;4(8):742-6. doi: 10.1021/ml400146c. PMID: 24900741; PMCID: PMC4027407.
In vivo protocol:
1. Korpela SP, Hinz TK, Oweida A, Kim J, Calhoun J, Ferris R, Nemenoff RA, Karam SD, Clambey ET, Heasley LE. Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response. J Transl Med. 2021 Jan 23;19(1):43. doi: 10.1186/s12967-021-02706-8. PMID: 33485341; PMCID: PMC7825244. 2. Mu Z, Klinowska T, Dong X, Foster E, Womack C, Fernandez SV, Cristofanilli M. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models. J Exp Clin Cancer Res. 2014 May 30;33(1):47. doi: 10.1186/1756-9966-33-47. PMID: 24886365; PMCID: PMC4061513.
1: Han C, Feng Z, Wang Y, Hu M, Xu S, Jiang F, Han Y, Liu Z, Li Y. Copper metabolism-related signature for prognosis prediction and MMP13 served as malignant factor for breast cancer. Heliyon. 2024 Aug 17;10(18):e36445. doi: 10.1016/j.heliyon.2024.e36445. PMID: 39315182; PMCID: PMC11417231. 2: Lin Z, Wu Z, Luo W. Bulk and single-cell sequencing identified a prognostic model based on the macrophage and lipid metabolism related signatures for osteosarcoma patients. Heliyon. 2024 Feb 18;10(4):e26091. doi: 10.1016/j.heliyon.2024.e26091. PMID: 38404899; PMCID: PMC10884844. 3: Pu L, Sun Y, Pu C, Zhang X, Wang D, Liu X, Guo P, Wang B, Xue L, Sun P. Machine learning-based disulfidptosis-related lncRNA signature predicts prognosis, immune infiltration and drug sensitivity in hepatocellular carcinoma. Sci Rep. 2024 Feb 22;14(1):4354. doi: 10.1038/s41598-024-54115-8. PMID: 38388539; PMCID: PMC10883983. 4: Pourjamal N, Yazdi N, Halme A, Joncour VL, Laakkonen P, Saharinen P, Joensuu H, Barok M. Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model. Clin Exp Metastasis. 2024 Apr;41(2):91-102. doi: 10.1007/s10585-024-10278-2. Epub 2024 Feb 17. PMID: 38367127; PMCID: PMC10973002. 5: Zhang W, Liu J, Ren X, Zhang Z, Zhou M, Li Y, Wang J, Li Q, Zhu Q, Wu G. Identification of the novel markers of PPAR signalling affecting immune microenvironment and immunotherapy response of lung adenocarcinoma patients. J Cell Mol Med. 2024 Mar;28(5):e17877. doi: 10.1111/jcmm.17877. Epub 2023 Aug 9. PMID: 37556076; PMCID: PMC10902583. 6: Black LE, Longo JF, Anderson JC, Carroll SL. Inhibition of Erb-B2 Receptor Tyrosine Kinase 3 and Associated Regulatory Pathways Potently Impairs Malignant Peripheral Nerve Sheath Tumor Proliferation and Survival. Am J Pathol. 2023 Sep;193(9):1298-1318. doi: 10.1016/j.ajpath.2023.05.016. Epub 2023 Jun 14. PMID: 37328102; PMCID: PMC10477957. 7: Attwa MW, AlRabiah H, Mostafa GAE, Kadi AA. Development of an LC-MS/MS Method for Quantification of Sapitinib in Human Liver Microsomes: In Silico and In Vitro Metabolic Stability Evaluation. Molecules. 2023 Mar 2;28(5):2322. doi: 10.3390/molecules28052322. PMID: 36903565; PMCID: PMC10005647. 8: Zheng C, Zhang G, Xie K, Diao Y, Luo C, Wang Y, Shen Y, Xue Q. Pan-Cancer Analysis and Experimental Validation Identify ACOT7 as a Novel Oncogene and Potential Therapeutic Target in Lung Adenocarcinoma. Cancers (Basel). 2022 Sep 18;14(18):4522. doi: 10.3390/cancers14184522. PMID: 36139682; PMCID: PMC9497106. 9: Singla H, Munshi A. HER2 Tyrosine Kinase Inhibitors in the Sensitization to Cancers Resistant to HER2 Antibodies. Crit Rev Oncog. 2020;25(3):241-250. doi: 10.1615/CritRevOncog.2020037108. PMID: 33463944. 10: Lee DW, Lee W, Kwon M, Lee HN. Dual inhibition of FOXM1 and its compensatory signaling pathway decreased the survival of ovarian cancer cells. Oncol Rep. 2021 Jan;45(1):390-400. doi: 10.3892/or.2020.7845. Epub 2020 Nov 11. PMID: 33200225. 11: Gao HL, Gupta P, Cui Q, Ashar YV, Wu ZX, Zeng L, Lei ZN, Teng QX, Ashby CR Jr, Guan Y, Chen ZS. Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter. Front Oncol. 2020 Oct 9;10:574861. doi: 10.3389/fonc.2020.574861. PMID: 33163405; PMCID: PMC7581728. 12: Yang Y, Choppavarapu L, Fang K, Naeini AS, Nosirov B, Li J, Yang K, He Z, Zhou Y, Schiff R, Li R, Hu Y, Wang J, Jin VX. The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cells. Biochim Biophys Acta Gene Regul Mech. 2020 Nov;1863(11):194631. doi: 10.1016/j.bbagrm.2020.194631. Epub 2020 Sep 19. PMID: 32956836; PMCID: PMC7686120. 13: Kim H, Choi JY, Rah YC, Ahn JC, Kim H, Jeong WJ, Ahn SH. ErbB3, a possible prognostic factor of head and neck squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020 Apr;129(4):377-387. doi: 10.1016/j.oooo.2019.12.006. Epub 2020 Feb 17. PMID: 32081558. 14: Attwa MW, Kadi AA. Sapitinib: reactive intermediates and bioactivation pathways characterized by LC-MS/MS. RSC Adv. 2019 Oct 16;9(57):32995-33006. doi: 10.1039/c9ra03926k. PMID: 35529145; PMCID: PMC9073192. 15: Cronise KE, Hernandez BG, Gustafson DL, Duval DL. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer. Mol Pharmacol. 2019 Jul;96(1):36-46. doi: 10.1124/mol.119.115808. Epub 2019 May 2. Erratum in: Mol Pharmacol. 2020 Jul;98(1):23. doi: 10.1124/mol.119.115808err. PMID: 31048548. 16: Puvanenthiran S, Essapen S, Seddon AM, Modjtahedi H. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs. Int J Oncol. 2016 Nov;49(5):1825-1838. doi: 10.3892/ijo.2016.3678. Epub 2016 Sep 5. PMID: 27599579; PMCID: PMC5063458. 17: Ghaly M, Seelemann C, Jahani-Asl A. A focused compound screen highlights the significance of epidermal growth factor receptor signalling in chordoma pathogenesis. J Pathol. 2016 Dec;240(4):381-383. doi: 10.1002/path.4780. Epub 2016 Oct 19. PMID: 27538356. 18: Scheipl S, Barnard M, Cottone L, Jorgensen M, Drewry DH, Zuercher WJ, Turlais F, Ye H, Leite AP, Smith JA, Leithner A, Möller P, Brüderlein S, Guppy N, Amary F, Tirabosco R, Strauss SJ, Pillay N, Flanagan AM. EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. J Pathol. 2016 Jul;239(3):320-34. doi: 10.1002/path.4729. Epub 2016 May 31. PMID: 27102572; PMCID: PMC4922416.